Cartesian Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Cartesian announced positive retreatment data for Descartes-08 in 5 myasthenia gravis patients who initially responded to treatment 16.6 months prior. Retreated patients achieved mean MG-ADL reduction of 6.6 points at Month 12 with no new safety signals; Phase 3 AURORA topline results expected Q1 2027.
Why this rating
Meaningful clinical validation of lead asset retreatment in orphan disease before pivotal Phase 3 readout. Positive data for $108.7M company approaching critical trial outcomes and BLA filing mid-2027.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.